Is Endocan a Biochemical Marker for Asymptomatic Target Organ Damage in Hypertensive Patients?

Overview

Journal Anatol J Cardiol

Publisher Kare Publishing

Specialty Cardiology & Vascular Diseases

Date 2019 Jan 30

PMID 30694799

Citations 3

Authors

Mustafa Tarik Agac

Behlul Kahyaoglu

Muhammed Murat Necati Aksoy

Fatma Behice Cinemre

Mehmet Bulent Vatan

Yasemin Gunduz

Affiliations

Soon will be listed here.

Abstract

Objective: Identification of the asymptomatic target organ damage (AOD) helps to stratify the overall risk of cardiovascular (CV) diseases and guides a treatment decision in hypertensive patients without a symptomatic CV or renal disease. The endothelial-cell-specific molecule 1 (endocan) is regarded as a novel marker of endothelial dysfunction. Its release is increased in hypertensive patients, especially those with symptomatic CV and renal disease. In the present study, we aimed to evaluate the endocan levels in asymptomatic hypertensive patients with or without AOD.

Methods: The study included 132 asymptomatic hypertensive patients, and 101 of who had at least one AOD.

Results: Serum endocan levels did not differ between patients with and without AOD (3.81±0.78 vs. 3.83±0.63 ng/mL, p=0.88). An analysis according to the presence of any specific AOD did not show any difference between groups. No significant correlation was found between serum endocan levels and any of the continuous variables related to AOD, such as the pulse pressure, carotid intimae-media thickness, cardio-ankle vascular index, ankle-brachial index, left ventricular mass index, Sokolow-Lyon index, Cornell voltage-duration product, and estimated glomerular filtration rate.

Conclusion: Endocan may not serve as a useful biomarker at asymptomatic vascular stages of hypertension, despite its role in indicating disease severity and inflammatory activation in advanced symptomatic CV and renal disease.

Citing Articles

Endocan as a marker of endothelial dysfunction in hypertension: a systematic review and meta-analysis.

Behnoush A, Khalaji A, Bahiraie P, Alehossein P, Shobeiri P, Peisepar M Hypertens Res. 2023; 46(10):2388-2399.

PMID: 37580451 DOI: 10.1038/s41440-023-01402-y.

The Role of Endocan in Cardiometabolic Disorders.

Klisic A, Patoulias D Metabolites. 2023; 13(5).

PMID: 37233681 PMC: 10224119. DOI: 10.3390/metabo13050640.

From Classic to Modern Prognostic Biomarkers in Patients with Acute Myocardial Infarction.

Statescu C, Anghel L, Tudurachi B, Leonte A, Benchea L, Sascau R Int J Mol Sci. 2022; 23(16).

PMID: 36012430 PMC: 9409468. DOI: 10.3390/ijms23169168.

References

Lewington S, Clarke R, Qizilbash N, Peto R, Collins R . Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002; 360(9349):1903-13. DOI: 10.1016/s0140-6736(02)11911-8. View

Hallan S, Asberg A, Lindberg M, Johnsen H . Validation of the Modification of Diet in Renal Disease formula for estimating GFR with special emphasis on calibration of the serum creatinine assay. Am J Kidney Dis. 2004; 44(1):84-93. DOI: 10.1053/j.ajkd.2004.03.027. View

Lang R, Bierig M, Devereux R, Flachskampf F, Foster E, Pellikka P . Recommendations for chamber quantification. Eur J Echocardiogr. 2006; 7(2):79-108. DOI: 10.1016/j.euje.2005.12.014. View

Sehestedt T, Jeppesen J, Hansen T, Wachtell K, Ibsen H, Torp-Pedersen C . Risk prediction is improved by adding markers of subclinical organ damage to SCORE. Eur Heart J. 2009; 31(7):883-91. DOI: 10.1093/eurheartj/ehp546. View

Shirai K, Hiruta N, Song M, Kurosu T, Suzuki J, Tomaru T . Cardio-ankle vascular index (CAVI) as a novel indicator of arterial stiffness: theory, evidence and perspectives. J Atheroscler Thromb. 2011; 18(11):924-38. DOI: 10.5551/jat.7716. View

Mancia G, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G . 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013; 34(28):2159-219. DOI: 10.1093/eurheartj/eht151. View

Balta I, Balta S, Demirkol S, Mikhailidis D, Celik T, Akhan M . Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease. Br J Dermatol. 2013; 169(5):1066-70. DOI: 10.1111/bjd.12525. View

Balta I, Balta S, Mustu Koryurek O, Demirkol S, Mikhailidis D, Celik T . Serum endocan levels as a marker of disease activity in patients with Behçet disease. J Am Acad Dermatol. 2013; 70(2):291-6. DOI: 10.1016/j.jaad.2013.09.013. View

Balta S, Mikhailidis D, Demirkol S, Ozturk C, Kurtoglu E, Demir M . Endocan--a novel inflammatory indicator in newly diagnosed patients with hypertension: a pilot study. Angiology. 2014; 65(9):773-7. DOI: 10.1177/0003319713513492. View

10.

Su Y, Shu K, Hu C, Cheng C, Wu M, Yu T . Serum Endocan correlated with stage of chronic kidney disease and deterioration in renal transplant recipients. Transplant Proc. 2014; 46(2):323-7. DOI: 10.1016/j.transproceed.2013.10.057. View

11.

Yilmaz M, Siriopol D, Saglam M, Kurt Y, Unal H, Eyileten T . Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease. Kidney Int. 2014; 86(6):1213-20. DOI: 10.1038/ki.2014.227. View

12.

Brandes R . Endothelial dysfunction and hypertension. Hypertension. 2014; 64(5):924-8. DOI: 10.1161/HYPERTENSIONAHA.114.03575. View

13.

Celik T, Balta S, Karaman M, Ay S, Demirkol S, Ozturk C . Endocan, a novel marker of endothelial dysfunction in patients with essential hypertension: comparative effects of amlodipine and valsartan. Blood Press. 2014; 24(1):55-60. DOI: 10.3109/08037051.2014.972816. View

14.

Kali A, Shetty K . Endocan: a novel circulating proteoglycan. Indian J Pharmacol. 2014; 46(6):579-83. PMC: 4264070. DOI: 10.4103/0253-7613.144891. View

15.

Wang X, Yang W, Luo T, Wang J, Jing Y . Serum endocan levels are correlated with the presence and severity of coronary artery disease in patients with hypertension. Genet Test Mol Biomarkers. 2015; 19(3):124-7. DOI: 10.1089/gtmb.2014.0274. View

16.

Xiong C, Zhao Z, Chen Z, Wu L, Luo Y, Hu F . Elevated Human Endothelial Cell-Specific Molecule-1 Level and Its Association With Coronary Artery Disease in Patients With Hypertension. J Investig Med. 2015; 63(7):867-70. DOI: 10.1097/JIM.0000000000000219. View

17.

Gkaliagkousi E, Gavriilaki E, Triantafyllou A, Douma S . Clinical Significance of Endothelial Dysfunction in Essential Hypertension. Curr Hypertens Rep. 2015; 17(11):85. DOI: 10.1007/s11906-015-0596-3. View

18.

Balta S, Mikhailidis D, Demirkol S, Ozturk C, Celik T, Iyisoy A . Endocan: A novel inflammatory indicator in cardiovascular disease?. Atherosclerosis. 2015; 243(1):339-43. DOI: 10.1016/j.atherosclerosis.2015.09.030. View

19.

Icli A, Cure E, Cumhur Cure M, Uslu A, Balta S, Mikhailidis D . Endocan Levels and Subclinical Atherosclerosis in Patients With Systemic Lupus Erythematosus. Angiology. 2015; 67(8):749-55. DOI: 10.1177/0003319715616240. View

20.

Ozalper V, Kara M, Tanoglu A, Cetindagli I, Ozturker C, Hancerli Y . Evaluation of endothelial dysfunction in patients with familial Mediterranean fever: the relationship between the levels of asymmetric dimethylarginine and endocan with carotid intima-media thickness and endothelium-dependent vasodilation. Clin Rheumatol. 2017; 36(9):2071-2077. DOI: 10.1007/s10067-016-3532-2. View